| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Supernus Pharmaceuticals Inc (NASDAQ: SUPN)
SUPN Technical Analysis
5
| As on 9th Jun 2023 SUPN SHARE Price closed @ 34.82 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 31.17 & Strong Buy for SHORT-TERM with Stoploss of 30.33 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SUPNSHARE Price
| Open | 35.60 | Change | Price | % |
| High | 35.88 | 1 Day | -0.77 | -2.16 |
| Low | 34.71 | 1 Week | 1.68 | 5.07 |
| Close | 34.82 | 1 Month | -2.12 | -5.74 |
| Volume | 391217 | 1 Year | 5.14 | 17.32 |
| 52 Week High 42.03 | 52 Week Low 25.33 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SUPN Daily Charts |
SUPN Intraday Charts |
Whats New @ Bazaartrend |
SUPN Free Analysis |
|
|
SUPN Important Levels Intraday
| RESISTANCE | 37.07 |
| RESISTANCE | 36.35 |
| RESISTANCE | 35.90 |
| RESISTANCE | 35.46 |
| SUPPORT | 34.18 |
| SUPPORT | 33.74 |
| SUPPORT | 33.29 |
| SUPPORT | 32.57 |
SUPN Forecast April 2024
| 4th UP Forecast | 43.07 |
| 3rd UP Forecast | 40.42 |
| 2nd UP Forecast | 38.79 |
| 1st UP Forecast | 37.15 |
| 1st DOWN Forecast | 32.49 |
| 2nd DOWN Forecast | 30.85 |
| 3rd DOWN Forecast | 29.22 |
| 4th DOWN Forecast | 26.57 |
SUPN Weekly Forecast
| 4th UP Forecast | 39.56 |
| 3rd UP Forecast | 38.04 |
| 2nd UP Forecast | 37.10 |
| 1st UP Forecast | 36.16 |
| 1st DOWN Forecast | 33.48 |
| 2nd DOWN Forecast | 32.54 |
| 3rd DOWN Forecast | 31.60 |
| 4th DOWN Forecast | 30.08 |
SUPN Forecast2024
| 4th UP Forecast | 67.85 |
| 3rd UP Forecast | 57.26 |
| 2nd UP Forecast | 50.71 |
| 1st UP Forecast | 44.16 |
| 1st DOWN Forecast | 25.48 |
| 2nd DOWN Forecast | 18.93 |
| 3rd DOWN Forecast | 12.38 |
| 4th DOWN Forecast | 1.79 |
Supernus Pharmaceuticals Inc ( NASDAQ USA Symbol : SUPN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SUPN Business Profile
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland. Address: 9715 Key West Avenue, Rockville, MD, United States, 20850
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service